Introducing From the Lab to the Jab: A new series of advocates’ guides
AVAC is excited to launch From the Lab to the Jab, a new series of advocates’ guides that highlight key advocacy issues to ensure equitable access to safe, effective, and affordable vaccines.
Co-created as part of our USAID-supported Coalition to Accelerate and Support Prevention Research (CASPR), with additional support from the New Venture Fund, From the Lab to the Jab issue briefs provide a roadmap for advocacy to advance the development and delivery of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines.
Go to avac.org/FromLabToJab to learn about next generation vaccine research and development; the basics of mRNA technology; initiatives that support local manufacturing; and understanding and overcoming barriers that undermine equitable access to vaccines. Each brief also highlights the advocacy needed to keep these efforts on track and in line with what communities need and want.
Stay tuned for an invitation to join the From the Lab to the Jab Webinar in January 2024, and be part of the conversation that will use these briefs to strengthen advocacy and create a roadmap to achieve key transformational priorities in global health.
On Transgender Day of Remembrance AVAC Announces TG ROAR 2023
Today, on Transgender Day of Remembrance (TDOR), as communities across the globe memorialize trans and gender nonconforming (TGNC) people targeted by violence and state-sanctioned bigotry, AVAC honors the trans community—those lost and those among us. We are committed, now more than ever, to fight these ongoing injustices and support TGNC advocates to lead on issues facing their communities.
Riding the momentum of the release of the No Data No More Manifesto and the Trans-Inclusivity Scorecard, AVAC is relaunching TG ROAR, a program from our larger PxROAR initiative, dedicated to supporting TGNC HIV advocates in Eastern and Southern Africa. The new eight-member cohort will campaign for trans-centered, HIV research and service delivery while addressing the social, political and economic barriers that all too often stand in the way.
Crimes against TGNC are on the rise as are rates of HIV incidence in trans populations. TGNC face unique barriers to testing, adherence to pre-exposure prophylaxis (PrEP) and maintaining viral suppression. Without meaningful trans inclusion in advocacy efforts there will be no epidemic control.
Learn more about AVAC’s new cohort of TG ROAR advocates here:
We continue to fight for transgender rights and invest in TGNC leadership to create a more equitable and just future for all.
Announcing the Good Participatory Practice Body of Evidence
We are thrilled to announce the Good Participatory Practice (GPP) Body of Evidence, a new online clearinghouse of case studies and analyses demonstrating the power of GPP, along with tools, templates and trainings for GPP implementation. The resources we’ve gathered for this much-needed “one-stop GPP shop” can be used to show the impact of GPP to date, how it can be measured going forward, and its practical application in real-time.
The Good Participatory Practice Guidelines have been shaping and improving HIV prevention research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.
But GPP implementation is far from easy. Because GPP looks different in every context and outcomes can be difficult to quantify, engagement work is often seen as secondary to clinical processes, and therefore undervalued and under-resourced. The GPP Body of Evidence demonstrates the contribution of GPP to the research enterprise, and the professionalization of GPP implementation.
Rest assured that this is not a one-off effort! Stay tuned for a webinar series in 2024 with key partners including WHO and Wellcome Trust that will highlight critical issues in stakeholder engagement in research, linking to corresponding resources from the Body of Evidence. And we’ll be keeping the Body of Evidence up to date – so please reach out if you have resources to add.
It’s time for GPP to become an international standard for clinical research. Making that case and making it happen, using the GPP Body of Evidence, has never been easier.
Ahead of World AIDS Day, Mitchell Warren spoke with POZ Magazine for a comprehensive look at where we are in the fight against HIV/AIDS and what advocacy and scientific breakthroughs are needed in ending the epidemic. “I think a lot about the progress we’ve achieved in providing ARVs worldwide, about what the global HIV response contributed to the COVID-19 response and continues to contribute to current conversations about preparing for future pandemics. It’s remarkable… And yet that progress has not been equitable and is not yet sustainable. What we’ve achieved today could slip away so quickly…”
PxPulse Podcast: Inclusion of Pregnant and Lactating People in HIV Research
The newest episode of our PxPulse podcast is out now! In this episode, experts discuss why pregnant and lactating people have been excluded from HIV research in the past, and what needs to change. The podcast features Anne Drapkin Lyerly of the PHASES Project, a participant from the HPTN 084 trial in Zimbabwe, Ashley Lima of USAID, Takunda Sola of the Zimbabwe MoH AIDS/TB Unit and AVAC’s Manju Chantani-Gada and Jeanne Baron.
Bhekisisa Podcast: The Anti-HIV Jab is Coming to South Africa
Advances in HIV prevention represent a huge opportunity to help get actual prevention choices into the hands of people. Listen to this podcast with Bhekisisa’s Mia Malan and in conversation with Mitchell Warren as they breakdown the complexity of issues in getting cabotegravir for PrEP available to those who want and need it as fast as possible.
Webinar Recording: Boo, Syphilis is Really Back!
AVAC, NACCHO and NNPTC also hosted a webinar on the increasing rates of Syphilis rates to share learnings on how others are addressing these rising rates and the techniques clinicians are using to detect, treat, and prevent infections.
Webinar Recording: Results from STI Landscaping Analyses in East and Southern Africa
Earlier this year, AVAC awarded seven teams funding to conduct projects in Southern and Eastern Africa to help understand the needs and evolving landscape around STI vaccines, diagnostics, and advocacy. These teams shared their findings and insights on two webinars that are not to be missed. Be sure to listen to the recordings, and to stay up to date with other STI events and resources by subscribing to our newsletter and visiting www.stiwatch.org.
Publication: Motivating Demand for the Dual Prevention Pill (DPP)
Multipurpose prevention technologies (MPTs) combining contraception with HIV prevention offer promising solutions to the challenges of adherence and uptake we’ve seen with oral PrEP. This new manuscript published in Frontiers in Reproductive Health by AVAC’s Wawira Nyagah, Kate Segal and partners shares findings to support a demand generation approach for the DPP (Dual Prevention Pill).
Webinar Recording: Where We Are in the PEPFAR Reauthorization
The reauthorization of PEPFAR—a program that just surpassed 20 years, has been a hot button topic both in the US and abroad. Listen to Practicality Over Panic: What Happens if PEPFAR is not Reauthorized, a candid discussion hosted by the Global Health Council and Global AIDS Policy Partnership and including AVAC’s Richard Muko on where things are at. And don’t miss AVAC’s PxPulse podcast episode, PEPFAR at 20: Keeping the promise, which explores important successes of PEPFAR and why the bipartisan program has been so fundamental in ending the epidemic.
Analysis: What You Need to Know About the Pandemic Accord
Negotiations around the Pandemic Accord are ongoing. Join us November 21 as we explore what’s in the Accord, what are the stakes, how can civil society engage, how will it affect our work. And to help make sense of it all, read the analysis by the Coalition of Advocates for Global Health and Pandemic Response, which is a compilation of recommendations from civil society and community organisations on the draft Negotiating Text of the WHO convention, agreement or other international instrument on pandemic prevention, preparedness, and response.
Mark Your Calendars: Upcoming Webinars
November 15, HPTN 096: Building Equity Through Advocacy – An Integrated, Status-Neutral Approach for Ending the Epidemic Among Black Gay Men in the South Join The Choice Agenda and partners for a fascinating discussion about a novel, much-needed HIV prevention research study – HPTN 096. Currently in the field, the study addresses social, structural, institutional, and behavioral barriers to HIV prevention and care. Co-sponsored by PrEP in Black America and Federal AIDS Policy Partnership Research Working Group.Register here.
November 15: Let’s Talk About HIV Cure Research Join Dr. Marina Caskey of Rockefeller University and members of the REACH Community Advisory Board as they review the current state of HIV cure research. This webinar is for any person interested in learning about what makes curing HIV so challenging, the strategies being pursued, and what is happening in NYC! Register here. A follow-on webinar is scheduled for November 29.
November 20: PrEP Resources Showcase Join AVAC and partners for a dynamic, workshop-style event exploring a digital collection of tools and resources on PrEP planning, access, trends in implementation research, and initiations to support robust access to PrEP and HIV prevention. Click here to register and learn more.
November 28: Spotlight on New PrEP Tools and Data: From R&D to access Between the recent accelerated growth in global PrEP initiations, and the introduction of new PrEP products like cabotegravir and the dapivirine vaginal ring, the field of PrEP data has never been more exciting or more complex. Join AVAC, the Medicines Patent Pool (MPP), and Unitaid to learn more about three important online PrEP resources and understand how they can support and enhance your work.
People who are pregnant or lactating (PLP) have historically been excluded from research because of concerns for the developing fetus. But this has led to a dearth of data on new interventions against health threats for this population. In the case of HIV, pregnancy raises the risk of acquiring HIV by up to three times, but providers often do not have the data to know whether a new intervention is safe or how it will work for pregnant patients. As a result, PLP and their physicians are left to make difficult decisions around the use of proven HIV prevention products as they await more data specific to pregnancy and lactation.
But change is in the air. Champions for the inclusion of PLP in research are paving the way for a paradigm shift— one that will redefine this population from needing protection from research to being better protected through research. In this episode of Px Pulse, AVAC’s Manju Chatani-Gada takes us through conversations with a trial participant who became pregnant, researchers, policy-makers and donors to understand why this population gets excluded, the impact it has, and what to do about it.
Tune in to hear
Dr. Anne Drapkin Lyerly, Principal Investigator of the PHASES Project to advance equitable inclusion of pregnant women in HIV research and its follow-on project, PREPARE, focused on ethical HIV research in adolescents who are pregnant.
Elisia Madende, Trial participant in the HPTN 084 trial in Zimbabwe
Dr. Ashley Lima, Health Science Specialist and Lead Technical Advisor for Socio-behavioral Research – USAID Office of HIV/AIDS Research Division
Dr. Takunda Sola, HIV Prevention and Key Populations Medical Officer- Zimbabwe MoH AIDS/TB Unit
More HIV prevention options are finally becoming available, including oral pills, injections and vaginal rings. Developing and delivering these options and making them actual choices for people, while also continuing to invest in the development of additional options to meet diverse needs has never been more promising or complex.
At AVAC, we know that products don’t end pandemics unless they are delivered with equity and urgency. We created PrEPWatch.org in 2007 to serve as a go-to resource for PrEP research, and it has expanded to include toolkits, guides, data, case studies and more to support efforts to improve access to PrEP. Our data, evidence and insights, based on lessons from oral PrEP, are intended to help get the rollout of next generation right this time.
Please join us and partners for a series of interactive sessions to guide you through these essential resources.
November 20, PrEP Resources Showcase
Calling for collaboration: This dynamic, workshop-style showcase is the first in a series that will feature multi-media presentations to take you through key resources including a toolkit to ensure programs related to sexual and reproductive health (SRH) and HIV prevention are well designed to reach and support adolescent girls and young women; and a comprehensive database for tracking PrEP uptake, implementation research and other critical data by country. Participants will get to dive deeply into specific resources, explore how they might use these in their work, and have an opportunity to provide input on what resources are still needed.
November 28, Spotlight on New Tools and Data: From R&D to Access
Staying on top of the latest data on PrEP initiations, the introduction of new PrEP products and the upstream pipeline of PrEP research and development is also both essential and complex. Advocates, researchers, funders and others working in HIV prevention must understand the trends and updates to do their job effectively—but how can you navigate the vast amount of PrEP data online?
Join AVAC, Unitaid, and the Medicines Patent Pool (MPP) to learn more about three complementary online PrEP resources and understand how they can support and enhance your work: PrEPWatch.org; Long-Acting Therapeutics Patents and Licenses Database (LAPaL) and the Access to Medicines Tracker — quarterly-update on regulatory filings, regulatory approvals and product supplies of MPP-licensed generic medicines at the country level.
We hope you’ll join us as we walk through ways you can use our resources to make this happen.
Vital Conversations in October and November: So many webinars, so little time!
The October and November calendar of webinars offers a wealth of conversations on cross-cutting issues facing advocates who care about global health equity and HIV prevention. From discussions on PEPFAR reauthorization, to an evolving picture on sexually transmitted infections, to case studies on new interventions at the intersection of HIV prevention and family planning, to research on barriers to care and health priorities for Black gay men in the US; it is a season for advocates to engage in shaping an agenda for 2024.
Scroll down for details and see you online!
October 26, Practicality over Panic: What happens if PEPFAR isn’t reauthorized?
At 11:00 AM ET: Join the Global AIDS Partnership (GAPP) for a candid assessment of the current landscape around PEPFAR, including the implications for work on the ground. It is intended to redirect anxiety into action and provide a reality check: PEPFAR is not going anywhere any time soon.
At 1:00 PM ET: Syphilis rates have increased drastically in recent years. Learn how others are addressing these rising rates and the techniques clinicians are using to detect, treat, and prevent infections. Co-hosted with NACCHO and NNPTC.
November 7, Results from STI Landscaping Analyses in East and Southern Africa—Part 1
At 9:00 AM ET: Hear results from STI landscaping projects conducted by AVAC partners in seven different East and Southern African countries that explored needs for STI vaccines and diagnostics.
November 9, Results from STI Landscaping Analyses in East and Southern Africa—Part 2
At 8:00 AM ET: Hear results from STI landscaping projects conducted by AVAC partners in seven different East and Southern African countries that explored needs for STI vaccines and diagnostics.
November 9, Pioneering Self-care Solutions to Drive Access to HIV Prevention and Family Planning
At 8:00 AM ET: This session will amplify lessons from five self-care interventions in family planning and HIV prevention — with case studies on specific interventions— DMPA-SC; the Caya Diaphragm; the Dual Prevention Pill; HIV self-testing; and Triggerise; an mHealth platform. Learn more about how these successful self-care strategies can be applied across diverse settings and join the discussion on the future of self-care in sexual and reproductive health. This session is part of the 2023 Self-Care Learning and Discovery Series. Learn more here.
November 15, HPTN 096: Building Equity Through Advocacy – An Integrated, Status-Neutral Approach for Ending the Epidemic Among Black Gay Men in the South
Announcing 5 New Advocacy Projects Devoted to Advancing Cure Research!
AVAC is excited to announce five new awards to accelerate advocacy for cure research.
Five alumni from AVAC and the International AIDS Society’s renowned Advocacy-For-Cure Academy program will now receive 10-month, $10,000 fellowship awards, to identify local needs and create solutions that advance HIV cure research in their local context. These fellowships are part of the overall Advocacy-For-Cure Academy, which is a training program to prepare a generation of cure advocates to fight effectively for research that matters to the people who are most impacted by HIV. Launched in 2018 by AVAC and IAS, this program has supported 96 alumni to attend five academies. To learn more about the academy program click here.
The first fellowships were issued to Cure Academy alumni in 2019 who have since developed training tools like the Series of Jojo, built partnerships between traditional healers and local researchers and promoted better understanding and translation of cure research by journalists.
Advocates and community leaders play an important role accelerating ethical research and creating an enabling environment that allows research to thrive. These fellows are building awareness among key stakeholders about the current landscape of HIV cure research and supporting the growing movement to build a cure agenda led by countries most affected by HIV.
Learn more about the newest cohort of fellows below.
Josephine Achieng
Josephine’s project uses a collaborative approach to promote HIV cure information and education for sex worker and other key population (KP) community advocates and health care workers for inclusive access to potential cures. Her project builds on former grantee Philister Adhiambo’s project to raise awareness and support among key populations. The project goal is to promote and strengthen efforts towards HIV cure research in Nairobi, Kenya.
Charles Brown
Charles’ HIV cure research advocacy focuses on increasing the participation of the community, policy makers and funders in HIV cure research engagement in Uganda. Charles will conduct interactive dialogues with HIV cure researchers to share information and simplify the HIV cure science while sharing opportunities to get engaged in the science. Charles will also build on advocacy efforts by past academy alumni to advance his work.
Gastón Devisich
Based in Buenos Aires, Argentenia, Gaston will work with regional alumni of IAS’ Research-for-a-Cure Academy and leading advocates and researchers to build The Latin American and the Caribbean HIV Cure Consortium. The Consortium will integrate and shed light on the work being conducted in the region and enhance collaborations to develop efficient, productive research and a strong advocacy agenda — producing a regional repository of HIV cure related resources in Spanish and Portuguese and a 2-year advocacy roadmap for the region.
Doreen Moraa
Doreen’s “”RAYS of Progress” is an HIV cure literacy project that aims to empower adolescents and young people living with HIV (AYPLHIVs) by delivering accessible information about current HIV cure research through social media platforms. She plans to meet with key stakeholders to elevate the importance of HIV cure research in Kenya. Her project, encompasses the aspect of hope, simplifying scientific concepts, encouraging involvement, and addressing stigma while showcasing the beauty of science in HIV cure research.
Kennedy Mupeli
Kennedy’s project aims to enhance cure literacy and advocacy skills among HIV long-term survivors (HTLS) in four regions of Botswana by training 40 participants in basic HIV and cure science. HTLS, who have lived with HIV for decades, provide invaluable insights into the disease’s progression and resilience, underscoring the importance of their inclusion in research. From this group, four core HIV Cure Champions will receive further advocacy training in cure research, targeting both local and national levels, and will lead a National Cure Advocacy Academy to build a Botswanan agenda.
These projects have been funded through the generous support of Aidsfund.
STIWatch Newsletter, October 2023
AVAC’s STIWatch newsletter is a curated resource on the latest in STI vaccines, diagnostics, and other prevention tools and strategies.
STIs and HIV are commonly linked and impact similar priority populations including young people, gay, bisexual, and other men who have sex with men, transgender people, and those living with HIV. To end the AIDS epidemic, there is great need to better prevent, detect, and treat STIs as having an STI can make it easier to get HIV. However, STI research and development lags behind HIV efforts, highlighting a need for new options and programs to better address both epidemics.
In 2022, AVAC launched an STI advocacy program to mobilize advocates to accelerate the development and equitable implementation of new STI vaccines, diagnostics, and other prevention options. Through this quarterly newsletter, we hope to share valuable information that sparks advocacy for a robust pipeline of interventions for STI prevention.
New Resources
Visit STIwatch.org, AVAC’s updated and expanded online resource to understand and advocate for research, development and rollout of STI vaccines and diagnostics. This site features updates on the status of vaccines and diagnostics for curable STIs including:
Information on chlamydia, gonorrhea, syphilis, trichomoniasis, and more.
An STI clinical trials dashboard that provides information about trials focused on STI vaccines, diagnostics, and DoxyPEP.
Updated graphics on the state of STI vaccines and diagnostic development.
STI Advocacy Updates
To understand the needs and evolving landscape around STI vaccines, diagnostics, and advocacy, AVAC awarded seven teams funding to conduct projects in South and Eastern Africa. Congratulations to Nyanza Reproductive Health Society in Kenya, Lesotho Network of AIDS Service Organizations in Lesotho, JournAIDS in Malawi, HIV Survivors and Partners Network in South Africa, ACTS 101 in Uganda, Latu Human Rights Foundation in Zambia, and Pangaea Zimbabwe in Zimbabwe.
These projects will help shed light on community needs and perceptions around STI advocacy; better understand issues and opportunities related to local STI vaccine and diagnostic research and development and identify areas to improve STI prevention efforts. Read more about the grantees and their landscaping work and join the webinar below.
Upcoming Events
What We’re Reading
JournAIDS calls for increased focus on STIs in Malawi. JournAIDS Program Manager, Dingani Mithi, recently spoke about results from an STI landscaping report that identified challenges and opportunities to improve STI prevention in Malawi. As STIs can increase HIV transmission, Mithi discussed the need for increased STI screening, treatment, and education programs to reduce HIV burden.
ASHM’s 2023 consensus statement on doxycycline prophylaxis (DoxyPEP). ASHM provides DoxyPEP recommendations for community and clinicians along with recommendations for research, guidelines, and policy. These recommendations are intended for gay, bisexual, and other men who have sex with men in Australia to prevent syphilis, chlamydia, and gonorrhea. Using DoxyPEP for a pre-defined period, continuing to promote STI screening, and the need for additional molecular tests to monitor AMR are all discussed within this guide.
To learn more about AVAC’s STI Program, visit STIwatch.org and avac.org/sti. Email sti@avac.org for questions or additional information. And to sign up for specific updates on STIs, click here.
Paving the Road for STI Prevention Advocacy
AVAC is thrilled to announce awards to seven advocacy partners in Southern and East Africa to conduct projects on community needs for the prevention of sexually transmitted infections (STIs). Join us November 7 and November 9 as our partners present insights from these surveys, and, together, we begin to build an advocacy agenda to accelerate development of new STI vaccines, diagnostics, and other prevention tools and strategies.
HIV is inextricably linked with other STIs. The same populations are disproportionately affected; experiences around stigma, shame, and lack of access can be remarkably similar, and STIs can increase HIV transmission and acquisition unless coupled with prevention methods like condoms and regular STI testing. Over the past decade, the global burden of STIs has increased dramatically, with the WHO estimating more than a million new cases acquired every day, while funding and other investments have lagged.
Advocacy is needed to bring more awareness on the impact that STIs have on the health of people and communities and the need for vaccines and diagnostics to better prevent, detect, and treat infections. These advocacy projects are helping build a stronger advocacy movement to help improve funding and commitments in and around STI vaccines and diagnostics.
The seven partners who will present their findings on the November calls include:
ACTS101, Uganda Team Members: Bridget Jjuuko Ndagaan, Shakira Namwanje, Arafat Kabugo
ACTS101 is engaging stakeholders across Uganda to assess and document the status of STI prevention awareness, research and development (R&D) capacity for STI prevention research, and challenges and opportunities to STI services. Learn more about ACTS101 on Twitter.
JournAIDS, Malawi Team Members: Dingaan Mithi, Christopher Bauti, Sosten Chilumpha
JournAIDS is evaluating how best to enhance STI prevention programs in Malawi and will document critical STI advocacy opportunities. The team will work with local development partners, donors, experts, civil society, scientists, researchers and the Malawi Ministry of Health to identify priorities and next steps for STI diagnostic R&D, prevention and treatment. Learn more about JournAIDS at their website.
Lesotho Network of AIDS Service Organizations (LENASO), Lesotho Team Members: Mamello G. Makoae, Katleho Ntheri, Tsepo Holoane, Tseliso Makoa, Nthabeleng Ntsekalle, Masheane Khasoane, Peter Raliile, Moleleki Thejane
LENASO is seeking to understand the community needs and landscape around common STIs in Lesotho in the district of Mokhotlong in Mapholaneng area where the big dam construction and mining projects are happening. LENASO is conducting interviews and focus groups for youth who are in and out of school, groups of girls and young women, and groups of males to understand the community needs and perceptions regarding STI advocacy, vaccines and diagnostics. Learn more about LENASO on Twitter @LENASO7.
HIV Survivors and Partners Network, South Africa Team Members: Mandisa Dukashe, Sakhile Xaba, Joy Neo Malesa, Khumalo Moqebelo, Phindile Nkambule
HIV Survivors and Partners Network is engaging diverse stakeholders, including government, civil society and HIV/STI implementing partners to identify community needs and perceptions around STI prevention, diagnosis and advocacy; examine challenges and opportunities related to local STI vaccine and diagnostic access; research and development needs; and opportunities to integrate existing community led programs. Learn more about the HIV Survivors and Partners Network at their website and on Facebook.
Pangaea Zimbabwe AIDS Trust (PZAT), Zimbabwe Team Members: Imelda Mahaka, Joseph Murungu, Barbra Ncube, Cleopatra Makura, Joseph Njowa
PZAT is conducting a national situation analysis to understand the strengths, gaps, needs, opportunities, and threats in implementing a successful program focused on STI prevention and management in Zimbabwe. The situation analysis will identify existing assets in the community that could support the implementation of STI prevention and management programs; identify gaps and unmet needs that can strengthen these programs; and understand the opportunities and threats that are affecting their implementation. Learn more about PZAT at their website and on Facebook and Twitter.
Nyanza Reproductive Health Society, Kenya Team Member: Simon Odiwuor Ondiek
This project is using mixed-methods to conduct a comprehensive landscape analysis to identify existing advocacy efforts for STI vaccines and diagnostics in Kenya. By assessing the landscape, evaluating gaps and challenges, and engaging key stakeholders, the project will develop actionable recommendations and an advocacy action plan. Ultimately, the project intends to foster collaboration among stakeholders, leading to a coordinated and impactful agenda for equitable access to STI prevention tools in Kenya. In this project, Simon and NRHS collaborates closely with the National AIDS & STIs Control Program (NASCOP), Kenya’s Government agency that focuses on coordinating and overseeing the country’s efforts to combat HIV/AIDS and Sexually Transmitted Infections (STIs). Learn more about Nyanza Reproductive Health Society at their website and on Facebook and Twitter.
Latu Human Rights Foundation, Zambia Team Member: Henry Sakala
The Latu Human Rights Foundation is examining community needs and perceptions around STI advocacy in the Lusaka Kabwe and Ndola Districts of Zambia. Findings from this landscape analysis will contribute to evidence-based decision-making, inform the development of targeted interventions, and strengthen the overall capacity of STI prevention advocacy programs in Zambia. Learn more about the Latu Human Rights Foundation on Facebook.
Investing in these advocates and partner organizations and in this advocacy is an urgent priority at AVAC. Their essential work lays the foundation for drawing critical resources to STI prevention, and accelerating the development of new vaccines, diagnostics, and other prevention tools and strategies. Their work and their voices will be instrumental to strengthening STI programs and equity in sexual health. We hope you’ll join us in congratulating these partners and hearing from them in November about this important work.
